基于多参数MRI的列线图预测前列腺癌主动监测患者病理升级风险的开发与外部验证
研究纳入开发队列300例(2010–2016年,Keimyung大学东三医院)和外部验证队列150例(2013–2017年,Kyungpook国立大学医院)接受主动监测的前列腺癌患者,构建并外部验证基于年龄、PSA、活检分级分组、PI-RADS评分、阳性针数及肿瘤累及针芯比例等常用临床和mpMRI因素的病理升级预测列线图。开发队列病理升级率25.0%,验证队列22.0%;列线图在外部验证队列的预测准确度(ROC AUC)为0.78。
要点
- 病理升级率:开发队列25.0%,外部验证队列22.0%。
- 基线PI-RADS 4分和5分、活检分级分组2、阳性针数>1、肿瘤累及≥50%的针芯是病理升级的显著预测因素。
- 列线图外部验证预测准确度ROC AUC为0.78。
关键影像表现/征象
- mpMRI上PI-RADS评分的进展与病理升级显著相关。
- 模型中显著变量包括年龄、前列腺特异性抗原水平、活检分级分组2、基线PI-RADS评分4分和5分、初次活检阳性针数大于1、活检针芯中肿瘤累及50%或以上。
诊断标准与关键数值
- 列线图预测病理升级风险的外部验证队列预测准确度(ROC AUC)为0.78。
临床应用与阅片要点
- 作者认为该列线图可能用于辅助主动监测前列腺癌患者的管理决策。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE. The aim of this study was to create, develop, and externally validate a nomogram that predicts pathologic upgrade in patients on active surveillance (AS) for prostate cancer using commonly available clinical and multiparametric MRI (mpMRI) factors. MATERIALS AND METHODS. A consecutive sample of 300 patients undergoing AS for prostate cancer at the Keimyung University Dongsan Hospital between 2010 and 2016 was used to develop the nomogram. The validation cohort consisted of 150 patients undergoing active surveillance at Kyungpook National University Hospital between 2013 and 2017. The study outcome was the occurrence of pathologic upgrade in AS patients. The relationship between the clinical and mpMRI factors considered and pathologic upgrade was tested using univariate and multivariate logistic regression analyses. The predictive accuracy of the nomogram was determined using the ROC AUC. RESULTS. The overall rate of pathologic upgrade was 25.0% in the developmental cohort and 22.0% in the validation cohort. Significant variables in the models were age, prostate-specific antigen level, biopsy grade group 2, baseline Prostate Imaging Reporting and Data System (PI-RADS) scores of 4 and 5, positive cores on initial biopsy greater than 1, and biopsy cores with 50% or more tumor involvement. The progression seen on mpMRI of PI-RADS score was significantly associated with pathologic upgrade. The nomogram used to predict the risk of pathologic upgrade had a predictive accuracy of 0.78 in the external validation cohort. CONCLUSION. This study developed and externally validated a nomogram that predicts the risk of pathologic upgrade on the basis of commonly used factors. This nomogram may be used to assist management decision making for patients on AS for prostate cancer.
引用
- Kim SH. Development and External Validation of Multiparametric MRI-Derived Nomogram to Predict Risk of Pathologic Upgrade in Patients on Active Surveillance for Prostate Cancer. AJR Am J Roentgenol. 2020. PMID: 31913073. doi:10.2214/AJR.19.22196
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。